Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neuralstem has received patent allowance for 'Compositions to Effect Neuronal Growth,' the compounds that effect neuronal growth.
Subscribe to our email newsletter
The patent includes both structure and method claims for inducing neurogenesis and the growth of new neurons, both in-vitro and in-vivo.
Neuralstem announces Notice of Allowance for two additional neurogenic compound patents.
The company’s first neurogenic patented compound, NSI-189 is currently in a Phase I FDA-approved safety trial in major depressive disorder.
The Phase Ib portion of the trial, in depressed patients, is likely to begin this fall .